/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Recent Developments In February 2024, our 67% owned subsidiary, Nascent Pharma, LLC ( Nascent ), acquired composition of matter and use patents covering liquid formulations of cannabis, including, among other things, beverages, tinctures, vape pen liquids and liquid filled capsules. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including canc…
$0.01
+$0.00 (+0.00%)
EOD Sep 1, 2026
The business is unprofitable at the operating level (-347.28% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 67.8% YoY. Margins deteriorated 135.4pp alongside, both lines moving the wrong way.
ROIC dropped from -191.69% to -287.97%, capital efficiency is deteriorating. Negative free cash flow of -$1M. The business is consuming cash, not generating it.
0.1x earnings, 2.1x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1M
▼ -67.8% YoY
Net Income (TTM)
-$13M
▲ +34.8% YoY
Op. Margin
-1035.91%
▼ -135.4pp YoY
ROIC
-7185.61%
▼ -96.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$246K
▲ +66.6% YoY
Op. Cash Flow (TTM)
$246K
▲ +67.0% YoY
Net Debt
-$8K
Net Cash Position
Cash & Equiv.
$8K
5Y CAGR: +26.4%
Continue Research
SourceComputed from the 10-Q filed 19 Nov 2024, covering the period ending 30 Sept 2024, as reported to the SEC. Data last refreshed 17 Aug 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 0.1 and a price-to-free-cash-flow of 2.1, Can B (NASC) trades below a two-stage DCF intrinsic value of about $0.09 per share, so at $0.01 the stock looks undervalued (1,074.0% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Can B scores 44/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $0.09 per share for NASC, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $0.07. At today's $0.01, that puts the stock about 1,074.0% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Can B scores 44 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -1,035.9% operating margin and a -7,185.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. NASC currently trades below its estimated intrinsic value and scores 44/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.